<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect</journal-id><journal-id journal-id-type="iso-abbrev">J. Infect</journal-id><journal-title-group><journal-title>The Journal of Infection</journal-title></journal-title-group><issn pub-type="ppub">0163-4453</issn><issn pub-type="epub">1532-2742</issn><publisher><publisher-name>The British Infection Association. Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7151357</article-id><article-id pub-id-type="publisher-id">S0163-4453(20)30154-7</article-id><article-id pub-id-type="doi">10.1016/j.jinf.2020.03.027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Herd immunity &#x02013; estimating the level required to halt the COVID-19 epidemics in affected countries</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Kwok</surname><given-names>Kin On</given-names></name><email>kkokwok@cuhk.edu.hk</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Lai</surname><given-names>Florence</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Wei</surname><given-names>Wan In</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Wong</surname><given-names>Samuel Yeung Shan</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Tang</surname><given-names>Julian W.T.</given-names></name><email>Julian.Tang@uhl-tr.nhs.uk</email><xref rid="aff0003" ref-type="aff">c</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0001"><label>a</label>JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China</aff><aff id="aff0002"><label>b</label>Department of Cardiovascular Sciences, University of Leicester, United Kingdom</aff><aff id="aff0003"><label>c</label>Respiratory Sciences, Clinical Microbiology, University of Leicester, 5/F Sandringham Building, Leicester Royal Infirmary, Leicester LE1 5WW, United Kingdom</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding authors. <email>kkokwok@cuhk.edu.hk</email><email>Julian.Tang@uhl-tr.nhs.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>21</day><month>3</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>3</month><year>2020</year></pub-date><volume>80</volume><issue>6</issue><fpage>e32</fpage><lpage>e33</lpage><history><date date-type="accepted"><day>18</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p content-type="salutation"><italic>Dear Editor</italic><bold>,</bold></p><p id="para0002">Previous workers have attempted to predict the cumulative number of cases of Coronavirus Disease 2019 (COVID-19) in China.<xref rid="bib0001" ref-type="bibr"><sup>1</sup></xref> However, since then, the epidemic has rapidly evolved into a pandemic affecting multiple countries worlwide.<xref rid="bib0002" ref-type="bibr"><sup>2</sup></xref> There have been serious debates about how to react to the spread of this disease, particularly by European countries, such as Italy, Spain, Germany, France and the UK, e.g. from closing schools and universities to locking down entire cities and countries. An alternative strategy would be to allow the causal virus (SARS-CoV-2) to spread to increase the population herd immunity, but at the same time protecting the elderly and those with multiple comorbidities, who are the most vulnerable to this virus.<xref rid="bib0003" ref-type="bibr"><sup>3</sup></xref>
</p><p id="para0003">Before initiating either of these strategies, we need to estimate the <italic>basic</italic> reproductive number (R<sub>0</sub>), or the more &#x02018;real-life&#x02019; <italic>effective</italic> reproductive number (R<sub>t</sub>) for a given population. R<sub>0</sub> is the number of secondary cases generated by the presence of one infected individual in an otherwise fully susceptible, well-mixed population. R<sub>t</sub> is a more practical real-life version of this, which uses real-life data (from diagnostic testing and/or clinical surveillance) to estimate the reproductive number for an ongoing epidemic.</p><p id="para0004">For this anaylsis, we will estimate R<sub>t</sub>, and we can do this by applying the exponential growth method,<xref rid="bib0004" ref-type="bibr"><sup>4</sup></xref> using data on the daily number of new COVID-19 cases, together with a recent estimate of the serial interval (mean&#x0202f;=&#x0202f;4.7 days, standard deviation&#x0202f;=&#x0202f;2.9 days),<xref rid="bib0005" ref-type="bibr"><sup>5</sup></xref> at a 0.05 significance level, with the mathematical software R (v3.6.1.).</p><p id="para0005">Using these values of R<sub>t</sub>, we can then calculate the minimum (&#x02018;critical&#x02019;) level of population immunity, P<sub>crit</sub>, acquired via vaccination or naturally-induced (i.e. after recovery from COVID-19), to halt the spread of infection in that population, using the formula: P<sub>crit</sub>=&#x000a0;1-(1/R<sub>t</sub>). So, for example, if the value of R<sub>t</sub>&#x000a0;=&#x000a0;3 then P<sub>crit</sub>=&#x000a0;0.67, i.e. at least two-thirds of the population need to be immune.<xref rid="bib0006" ref-type="bibr"><sup>6</sup></xref>
</p><p id="para0006">As of 13 March 2020, there were 32 countries outside China with over 100 COVID-19 cases.<xref rid="bib0007" ref-type="bibr"><sup>7</sup></xref> The seven countries with the highest number of infections were: the United States (<italic>n</italic>&#x0202f;=&#x0202f;2294), France (<italic>n</italic>&#x0202f;=&#x0202f;3671), Germany (<italic>n</italic>&#x0202f;=&#x0202f;3675), Spain (<italic>n</italic>&#x0202f;=&#x0202f;5232), Korea (<italic>n</italic>&#x0202f;=&#x0202f;8086), Iran (<italic>n</italic>&#x0202f;=&#x0202f;11,364) and Italy (<italic>n</italic>&#x0202f;=&#x0202f;17,660). The number of confirmed cases in the other 25 countries were less than 1200 (<xref rid="tbl0001" ref-type="table">Table 1</xref>
).<table-wrap position="float" id="tbl0001"><label>Table 1</label><caption><p>Estimates of SARS-CoV-2 effective reproduction number (R<sub>t</sub>) of 32 study countries (as of 13 March 2020,<xref rid="bib0007" ref-type="bibr"><bold><sup>7</sup></bold></xref>), and the minimum proportion (Pcrit, as% of population) needed to have recovered from COVID-19 with subsequent immunity, to halt the epidemic in that population.</p></caption><alt-text id="alt0001">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Study countries</th><th valign="top">Population infected by COVID-19</th><th valign="top">Estimates of effective reproduction number (R<sub>t</sub>) (95% CI), (<italic>n</italic>&#x0202f;=&#x0202f;32)</th><th valign="top">Minimum proportion (%) of total population required to recover from COVID-19 to confer immunity (P<sub>crit</sub>)</th></tr></thead><tbody><tr><td valign="top"><bold>R<sub>t</sub> &#x0003e;4</bold></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Bahrain</td><td valign="top">210</td><td valign="top">6.64 (5.20, 8.61)</td><td valign="top">85.0</td></tr><tr><td valign="top">Slovenia</td><td valign="top">141</td><td valign="top">6.38 (4.91, 8.38)</td><td valign="top">84.3</td></tr><tr><td valign="top">Qatar</td><td valign="top">320</td><td valign="top">5.38 (4.59, 6.34)</td><td valign="top">81.4</td></tr><tr><td valign="top">Spain</td><td valign="top">5232</td><td valign="top">5.17 (4.98, 5.37)</td><td valign="top">80.7</td></tr><tr><td valign="top">Denmark</td><td valign="top">804</td><td valign="top">5.08 (4.60, 5.62)</td><td valign="top">80.3</td></tr><tr><td valign="top">Finland</td><td valign="top">155</td><td valign="top">4.52 (3.72, 5.56)</td><td valign="top">77.9</td></tr><tr><td valign="top"><bold>R<sub>t</sub> (2&#x02013;4)</bold></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Austria</td><td valign="top">504</td><td valign="top">3.97 (3.56, 4.42)</td><td valign="top">74.8</td></tr><tr><td valign="top">Norway</td><td valign="top">996</td><td valign="top">3.74 (3.47, 4.04)</td><td valign="top">73.3</td></tr><tr><td valign="top">Portugal</td><td valign="top">112</td><td valign="top">3.68 (2.86, 4.75)</td><td valign="top">72.8</td></tr><tr><td valign="top">Czech Republic</td><td valign="top">141</td><td valign="top">3.57 (2.88, 4.45)</td><td valign="top">72.0</td></tr><tr><td valign="top">Sweden</td><td valign="top">814</td><td valign="top">3.44 (3.20, 3.71)</td><td valign="top">70.9</td></tr><tr><td valign="top">The United States</td><td valign="top">2294</td><td valign="top">3.29 (3.15, 3.43)</td><td valign="top">69.6</td></tr><tr><td valign="top">Germany</td><td valign="top">3675</td><td valign="top">3.29 (3.18, 3.40)</td><td valign="top">69.6</td></tr><tr><td valign="top">Switzerland</td><td valign="top">1139</td><td valign="top">3.26 (3.05, 4.78)</td><td valign="top">69.3</td></tr><tr><td valign="top">Brazil</td><td valign="top">151</td><td valign="top">3.26 (2.99, 3.55)</td><td valign="top">69.3</td></tr><tr><td valign="top">Netherlands</td><td valign="top">804</td><td valign="top">3.25 (3.02, 3.51)</td><td valign="top">69.2</td></tr><tr><td valign="top">Greece</td><td valign="top">190</td><td valign="top">3.12 (2.67, 3.67)</td><td valign="top">67.9</td></tr><tr><td valign="top">France</td><td valign="top">3661</td><td valign="top">3.09 (2.99, 3.19)</td><td valign="top">67.6</td></tr><tr><td valign="top">Israel</td><td valign="top">143</td><td valign="top">3.02 (2.56, 3.59)</td><td valign="top">66.9</td></tr><tr><td valign="top">The United Kingdom</td><td valign="top">798</td><td valign="top">2.90 (2.72, 3.10)</td><td valign="top">65.5</td></tr><tr><td valign="top">Italy</td><td valign="top">17,660</td><td valign="top">2.44 (2.41, 2.47)</td><td valign="top">59.0</td></tr><tr><td valign="top">Canada</td><td valign="top">198</td><td valign="top">2.30 (2.07, 2.57)</td><td valign="top">56.5</td></tr><tr><td valign="top">Iceland</td><td valign="top">134</td><td valign="top">2.28 (1.90, 2.75)</td><td valign="top">56.1</td></tr><tr><td valign="top"><bold>R<sub>t</sub> (1&#x02013;2)</bold></td><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Iran</td><td valign="top">11,364</td><td valign="top">2.00 (1.96, 2.03)</td><td valign="top">50.0</td></tr><tr><td valign="top">Australia</td><td valign="top">199</td><td valign="top">1.86 (1.71, 2.03)</td><td valign="top">46.2</td></tr><tr><td valign="top">Belgium</td><td valign="top">559</td><td valign="top">1.75 (1.55, 1.97)</td><td valign="top">42.9</td></tr><tr><td valign="top">Malaysia</td><td valign="top">197</td><td valign="top">1.74 (1.61, 1.88)</td><td valign="top">42.5</td></tr><tr><td valign="top">Iraq</td><td valign="top">101</td><td valign="top">1.67 (1.41,1.97)</td><td valign="top">40.1</td></tr><tr><td valign="top">Japan</td><td valign="top">734</td><td valign="top">1.49 (1.44, 1.54)</td><td valign="top">32.9</td></tr><tr><td valign="top">Korea</td><td valign="top">8086</td><td valign="top">1.43 (1.42, 1.45)</td><td valign="top">30.1</td></tr><tr><td valign="top">Singapore</td><td valign="top">200</td><td valign="top">1.13 (1.06, 1.19)</td><td valign="top">11.5</td></tr><tr><td valign="top">Kuwait</td><td valign="top">100</td><td valign="top">1.06 (0.89, 1.26)</td><td valign="top">5.66</td></tr></tbody></table></table-wrap></p><p id="para0007">Exploring these parameters and their implications further, the difference between R<sub>0</sub> and R<sub>t</sub> is related to the proportion of individuals that are already immune (either by vaccination or natural infection) to that pathogen in that population. So another way of calculating R<sub>t</sub> for a pathogen in a given population is by multiplying R<sub>0</sub> by the proportion of that population that is non-immune (i.e. susceptible) to that pathogen.<xref rid="bib0006" ref-type="bibr"><sup>6</sup></xref> Hence, R<sub>0</sub> will only equal R<sub>t</sub> when there are no immune individuals in the population (i.e. when all are susceptible). This means that any partial, pre-existing immunity to the infecting agent can reduce the number of expected secondary cases arising.</p><p id="para0008">Although SARS-CoV-2 is a new coronavirus, one source of possible partial immunity to is some possible antibody cross-reactivity and partial immunity from previous infections with the common seasonal coronaviruses (OC43, 229E, NL63, HKU1) that have been circulating in human populations for decades, as was noted for SARS-CoV.<xref rid="bib0008" ref-type="bibr"><sup>8</sup></xref> This could also be the case for SARS-CoV-2 and might explain why some individuals (perhaps those who have recently recovered from a seasonal coronavirus infection) have milder or asymptomatic infections.<xref rid="bib0009" ref-type="bibr"><sup>9</sup></xref>
</p><p id="para0009">Finally, returning to the concept of enhancing herd immunity to control the COVID-19 epidemic, given that the case fatality rate (CFR) of COVID-19 can be anything between 0.25&#x02013;3.0% of a country's population,<xref rid="bib0010" ref-type="bibr"><sup>10</sup></xref> the estimated number of people who could potentially die from COVID-19, whilst the population reaches the P<sub>crit</sub> herd immunity level, may be difficult to accept.<xref rid="bib0003" ref-type="bibr"><sup>3</sup></xref>
</p></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><label>1</label><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Ying</surname><given-names>Q.</given-names></name><name><surname>Zeng</surname><given-names>T.</given-names></name><name><surname>Long</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Simulating and forecasting the cumulative confirmed cases of SARS-CoV-2 in China by Boltzmann function-based regression analyses</article-title><source>J Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.02.019</pub-id><comment>pii: S0163-4453(20)30098-0</comment></element-citation></ref><ref id="bib0002"><label>2</label><element-citation publication-type="book" id="sbref0002"><person-group person-group-type="author"><collab><italic>COVID-19 situation in the WHO European Region</italic></collab></person-group><year>2020</year><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="bib0003"><label>3</label><mixed-citation publication-type="other" id="othref0001">Coronavirus: some scientists say UK virus strategy is `risking lives'. <ext-link ext-link-type="uri" xlink:href="https://www.bbc.co.uk/news/science-environment-51892402" id="interref0001">https://www.bbc.co.uk/news/science-environment-51892402</ext-link>. Accessed 14 March2020.</mixed-citation></ref><ref id="bib0004"><label>4</label><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Wallinga</surname><given-names>J.</given-names></name><name><surname>Lipsitch</surname><given-names>M.</given-names></name></person-group><article-title>How generation intervals shape the relationship between growth rates and reproductive numbers</article-title><source>Proc Biol Sci</source><volume>274</volume><issue>1609</issue><year>2007</year><fpage>599</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">17476782</pub-id></element-citation></ref><ref id="bib0005"><label>5</label><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Nishiura</surname><given-names>H.</given-names></name><name><surname>Linton</surname><given-names>N.M.</given-names></name><name><surname>Akhmetzhanov</surname><given-names>A.R.</given-names></name></person-group><article-title>Serial interval of novel coronavirus (COVID-19) infections</article-title><source>Int J Infect Dis</source><year>2020</year></element-citation></ref><ref id="bib0006"><label>6</label><element-citation publication-type="book" id="sbref0005"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>R.M.</given-names></name><name><surname>May</surname><given-names>R.M.</given-names></name></person-group><chapter-title>Infectious Diseases of Humans: Dynamics and Control</chapter-title><year>1992</year><publisher-name>Oxford Science Publications</publisher-name><publisher-loc>Oxford, UK</publisher-loc><fpage>768</fpage><comment>ISBN-10: 019854040X. ISBN-13: 978-0198540403</comment></element-citation></ref><ref id="bib0007"><label>7</label><element-citation publication-type="book" id="sbref0006"><person-group person-group-type="author"><collab>ProMED-mail</collab></person-group><chapter-title>COVID-19 update (39): global, more countries, stability, mitigation impact</chapter-title><year>2020</year><publisher-name>WHO</publisher-name><comment>Archive No. 20200314.7088746</comment></element-citation></ref><ref id="bib0008"><label>8</label><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>B.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M.A.</given-names></name></person-group><article-title>Serological assays for emerging coronaviruses: challenges and pitfalls</article-title><source>Virus Res</source><volume>194</volume><year>2014</year><fpage>175</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.03.018</pub-id><pub-id pub-id-type="pmid">24670324</pub-id></element-citation></ref><ref id="bib0009"><label>9</label><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name></person-group><article-title>Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing</article-title><source>China. Sci China Life Sci</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s11427-020-1661-4</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="bib0010"><label>10</label><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>N.</given-names></name><name><surname>Kvalsvig</surname><given-names>A.</given-names></name><name><surname>Barnard</surname><given-names>L.T.</given-names></name><name><surname>Baker</surname><given-names>M.G.</given-names></name></person-group><article-title>Case-Fatality risk estimates for COVID-19 calculated by using a lag time for fatality</article-title><source>Emerg Infect Dis</source><volume>26</volume><issue>6</issue><year>2020</year><pub-id pub-id-type="doi">10.3201/eid2606.200320</pub-id><comment>[Epub ahead of print]</comment></element-citation></ref></ref-list></back></article>